Skip to content
+1 416-961-JOIN (5646)info@JoinAStudy.ca+1 416-961-JOIN (5646)
Facebook page opens in new windowX page opens in new windowInstagram page opens in new windowYouTube page opens in new window
Facebook page opens in new windowX page opens in new windowInstagram page opens in new windowYouTube page opens in new window
JoinAStudy.ca
JoinAStudy.ca
JoinAStudy.ca – Help create a healthier future
JoinAStudy.caJoinAStudy.ca
  • Home
  • Current Studies
  • Medical Conditions
  • Study Locations
  • Health Blog
  • Why JoinAStudy?
Search:
info@JoinAStudy.ca
Search:
Search:
JoinAStudy.ca JoinAStudy.ca JoinAStudy.caJoinAStudy.ca
  • Home
  • Current Studies
  • Medical Conditions
  • Study Locations
  • Health Blog
  • Why JoinAStudy?
+1 416-961-JOIN (5646)info@JoinAStudy.ca
Facebook page opens in new windowX page opens in new windowInstagram page opens in new windowYouTube page opens in new window

Daily Archives: <span>March 22, 2022</span>

You are here:
  1. Home
  2. March 2022

Semaglutide weight loss

Paxlovid – Pfizer’s New Oral Covid Pill

COVID, Drug Development, Health Canada & FDA, Industry News, Study ResultsBy JoinAStudy TeamMarch 22, 2022

Canada has approved the first oral COVID-19 treatment that can be taken at home. The drug, an antiviral developed by Pfizer, was found to reduce risk of hospitalization and death by 89 percent in clinical trials.   At the moment, there is a “limited global supply” of the drug, thus Canadian health officials have prioritized the

© Copyright - JoinAStudy.ca, 2018. All rights reserved
Designed by Pixelore.ca

JoinAStudy.ca does not provide medical advice, diagnosis or treatment.

Information Disclaimer | Privacy | Contact Us

Go to Top
  • English
  • Français